Adverum Biotechnologies to Present at Upcoming Conferences
Event: | Cell & Gene Meeting on the Mesa | ||
Date: | October 5, 2017 | ||
Time: | 2:15 – 2:30 p.m. PT | ||
Location: | La Jolla, CA | ||
Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
Event: | Chardan Gene Therapy Conference | ||
Date: | October 10, 2017 | ||
Time: | 2:00 – 2:25 p.m. ET | ||
Location: | New York, NY | ||
Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
Event: | Jefferies Gene Technology Summit Conference | ||
Date: | October 12, 2017 | ||
Location: | New York, NY | ||
Panel: | Mehdi Gasmi, Ph.D., chief science and technology officer |
A live and replay video webcast of the Cell & Gene Meeting on the
A live and replay audio webcast of the
About
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Adverum Contact:Charles Butler Vice President, Investor Relations & Corporate Communications 650-272-6260 cbutler@adverum.com
Source: Adverum Biotechnologies, Inc.